loading page

COST-EFFECTIVENESS OF OMALIZUMAB FOR THE TREATMENT OF SEVERE PEDIATRIC ALLERGIC ASTHMA- RESULTS OF A REAL-LIFE STUDY IN SPAIN
  • +29
  • Antonio Nieto,
  • María Nieto-Cid,
  • Teresa Garriga-Baraut,
  • Ana Plaza,
  • Miguel Tortajada,
  • Javier Torres-Borrego,
  • Lozano Jaime,
  • Laura Moreno-Galarraga,
  • Mar Folque,
  • Montserrat Bosque,
  • Mirella Gaboli,
  • Alejandro López Neyra,
  • Cristina Rivas-Juesas,
  • María Araceli Caballero-Rabasco,
  • Andrea Freixa,
  • Laura Valdesoiro Navarrete,
  • Esther Ballester Asensio,
  • María Penín Antón,
  • Raquel Romero,
  • Juan Navarro Morón,
  • Alfredo Valenzuela-Soria,
  • Mercedes Sánchez Mateos,
  • José Batlles Garrido,
  • Verónica Sanz Santiago,
  • Álvaro Gimeno Díaz de Atauri,
  • Anselmo Andrés Martín,
  • Elena Campos Alonso,
  • David Gómez-Pastrana,
  • Elena Vázquez Rodríguez,
  • Luz Martínez-Pardo,
  • Genoveva del Río Camacho,
  • Angel Mazón Ramos
Antonio Nieto
Hospital Universitari i Politecnic La Fe
Author Profile
María Nieto-Cid
Hospital Universitari i Politecnic La Fe
Author Profile
Teresa Garriga-Baraut
Hospital Universitari i Politecnic La Fe
Author Profile
Ana Plaza
Hospital Sant Joan de Deu Servei d'Allergia i Immunologia Clinica
Author Profile
Miguel Tortajada
Hospital Universitario Doctor Peset
Author Profile
Javier Torres-Borrego
Hospital Universitario Reina Sofia
Author Profile
Lozano Jaime
Hospital Sant Joan de Deu Servei d'Allergia i Immunologia Clinica
Author Profile
Laura Moreno-Galarraga
Complejo Hospitalario de Navarra IdiSNA Health Research Institute
Author Profile
Mar Folque
Hospital Sant Joan de Deu Servei d'Allergia i Immunologia Clinica
Author Profile
Montserrat Bosque
Hospital de Sabadell
Author Profile
Mirella Gaboli
Hospital Universitario Virgen del Rocio
Author Profile
Alejandro López Neyra
Hospital Universitario Ramon y Cajal
Author Profile
Cristina Rivas-Juesas
Hospital de Sagunto
Author Profile
María Araceli Caballero-Rabasco
Hospital del Mar
Author Profile
Andrea Freixa
Hospital Infantil i l'Hospital de la Dona de Vall d'Hebron
Author Profile
Laura Valdesoiro Navarrete
Hospital de Sabadell
Author Profile
Esther Ballester Asensio
Hospital Universitario Doctor Peset
Author Profile
María Penín Antón
Hospital Universitario Principe de Asturias
Author Profile
Raquel Romero
Hospital Universitario San Cecilio
Author Profile
Juan Navarro Morón
Hospital Costa del Sol
Author Profile
Alfredo Valenzuela-Soria
Hospital Universitario Virgen de las Nieves
Author Profile
Mercedes Sánchez Mateos
Hospital Universitario Puerta de Hierro Majadahonda
Author Profile
José Batlles Garrido
Complejo Hospitalario Torrecardenas
Author Profile
Verónica Sanz Santiago
Hospital Infantil Universitario Nino Jesus
Author Profile
Álvaro Gimeno Díaz de Atauri
Hospital Universitario 12 de Octubre
Author Profile
Anselmo Andrés Martín
Hospital Universitario Virgen Macarena
Author Profile
Elena Campos Alonso
Hospital Comarcal Virgen de la Merced
Author Profile
David Gómez-Pastrana
Hospital Universitario de Jerez de la Frontera
Author Profile
Elena Vázquez Rodríguez
Hospital Universitario de Valme
Author Profile
Luz Martínez-Pardo
Complejo Hospitalario de Jaen
Author Profile
Genoveva del Río Camacho
Hospital Universitario Fundacion Jimenez Diaz
Author Profile
Angel Mazón Ramos
Hospital Universitari i Politecnic La Fe

Corresponding Author:[email protected]

Author Profile

Abstract

BACKGROUND Severe Pediatric Allergic Asthma (SPAA) induces a huge economic burden in terms of direct, indirect and intangible costs. The use of omalizumab for the treatment of these patients has produced a significant improvement in several clinical outcomes, but at the same time, the cost for the management of the disease has also increased. The aim of this report was to evaluate whether the use of omalizumab is cost-effective. METHODS A sample of 426 children with SPAA from the ANCHORS study was used to calculate the Incremental Cost Effectiveness Ratio (ICER) for the avoidance of Moderate to Severe Exacerbations (MSE), and also for the improvement in childhood Asthma Control Test (c-ACT) or the Asthma Control Questionnaire (ACQ5). We retrospectively collected data of health encounters and drug consumption before and up to six years after the beginning of the treatment with omalizumab. RESULTS The ICER per avoided MSE was \euro2,107 after one year, and it consistently decreased to \euro656 in those followed up to six years. Similarly, the ICER for the Minimally Important Difference in control tests showed a decrease from \euro2,059 to \euro380 per each 0.5 points of improvement in ACQ5, and from \euro3,141 to \euro2,322 per each 3 points improvement in c-ACT, at years 1 and 6 respectively. CONCLUSION The use of OMZ is a cost-effective option for most children with uncontrolled SPAA, mainly those who have frequent exacerbations, showing progressively reduced costs in successive years of treatment.
24 Jan 2023Submitted to Pediatric Allergy and Immunology
24 Jan 2023Submission Checks Completed
24 Jan 2023Assigned to Editor
24 Jan 2023Review(s) Completed, Editorial Evaluation Pending
25 Jan 2023Reviewer(s) Assigned
13 Feb 2023Editorial Decision: Revise Minor
06 Mar 20231st Revision Received
06 Mar 2023Submission Checks Completed
06 Mar 2023Assigned to Editor
06 Mar 2023Review(s) Completed, Editorial Evaluation Pending
08 Mar 2023Editorial Decision: Accept